News
We send the latest information from SMC Laboratories.
The STAM™ mouse: a clinically relevant, spontaneous HCC model
We would like to introduce a study published by our client using our STAM™ mouse (Dow, et al. Proc Natl Acad Sci U S A. 2018). Title: Integrative genomic analysis of mouse and human hepatocellular carcinoma Dow, et al. Proc Natl Acad Sci U S A. 2018 The STAM™ model is a…
Introducing our skin disease model: Imiquimod (IMQ)-induced psoriasis model
Today, from our lineup of pathological models, we would like to introduce the imiquimod (IMQ)-induced dermatitis model for psoriasis. Psoriasis is a refractory skin disease that is caused by both genetic and environmental factors. It causes chronic inflammation characterized by the clinical appearance of erythema and scaling of the skin. It is…
MOA demonstration #3 【GLP-1】｜Evaluation of GLP-1 targeted MASH treatment efficacy using STAM™ mice
Today, we introduce the pre-clinical studies in MASH drug development targeting GLP-1. Speaking of GLP-1, Wegovy® (semaglutide), approved by the FDA for the treatment of obesity, is a GLP-1 receptor agonist. GLP-1 receptor agonists such as semaglutide were initially developed for the treatment of diabetes, but drug discovery research has been conducted to expand…
Custom Model Service and its case study “CAIA-Rheumatoid Arthritis Model”
In recent years, we have received many requests about our services, starting from the establishment of pathological models, in response to the increasing diversity of diseases and the needs for therapeutic drug development. Therefore, today we would like to introduce an example study regarding custom model services, for which we have received many inquiries. …
MOA demonstration #2【diponectin】｜A drug efficacy evaluation study using STAM™ mice “Inhibition of MASH and fibrosis progression by adiponectin-derived peptide”.
We introduce the pre-clinical studies in MASH drug development using Adiponectin, adipoR1 , adipoR2, etc. as MOA. Demonstration of adiponectin-derived peptide ALY688 in a drug evaluation study using STAM™ mice ►The adiponectin‐derived peptide ALY688 protects against the development of metabolic dysfunction‐associated steatohepatitis – Huang – 2024 – Clinical and Translational Science – Wiley Online…
Announcement of webinar: THRβ agonist and preclinical pharmacology study using by STAM™ mice
Today, we are excited to invite you to join our webinar that will be taking place on June 20 from 9:30 AM (JST). In this webinar, we will introduce the THRβ agonist and preclinical pharmacology study. It has been several months since Resmetirom was approved by the FDA as the first MASH treatment. We will…
Drug efficacy evaluation study for fibrotic diseases involving multiple organs
If the therapeutic drug you are developing targets a factor that is related to a multi-organ pathology, such as inflammation or fibrosis, our services for drug evaluation studies can help to bring out the maximal efficacy. Today, we want to introduce a paper by Insilico Medicine, a company that focuses on fibrosis to develop…
Poster presentation selected for the EASL Congress 2024, data on STAM mice in the field of Immune-oncology
We are pleased to announce that the latest pathology and pathogenesis data in the field of immuno-oncology on STAM™-HCC/IO⁺ mouse will be presented in a poster at the EASL Congress 2024 in Milan, Italy, June 5-8, 2024. The STAM™-HCC/IO⁺ mouse is the first preclinical model in the field of immuno-oncology for the development of new…
SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology
We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology from May 9th (Thu) to 11th (Sat). In the Exhibition section, we will introduce our drug efficacy evaluation study services using our original MASH (NASH)-hepatocarcinoma model, STAM™ mouse, as well as other…
【Breaking News!】 First MASH treatment approved by FDA
On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH. ► FDA NEWS RELEASE FDA approved first MASH treatment It took more than 15 years for Rezdiffra to be approved for the treatment of MASH,…